Prot# 102-21: An Open Label Study of the Efficacy and Safety of Re-Treatments with Rituximab (MabThera®/Rituxan®) in Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies

Project: Research project

Project Details

StatusFinished
Effective start/end date6/23/049/9/10

Funding

  • Biogen Inc. (102-21)